



**Oxford BioDynamics**

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

**Response to Share Price Movement**

**Oxford, UK - 3 December 2024** - Oxford BioDynamics, Plc (AIM: OBD, the Company) a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform notes the recent movement in the share price. As per the announcement issued on 14 October 2024, the Company is continuing to explore a number of different options to bring additional near-term funding into the business. The Board is mindful that market conditions remain challenging and therefore there is no guarantee of a successful conclusion. As previously announced the Company will require additional cash resources by early Q1 of 2025. The Board will provide further updates as appropriate.

**-Ends-**

**For more information:**

**Oxford BioDynamics Plc**

+44 (0)1865 518910

Jon Burrows, CEO

Paul Stockdale, CFO

**Shore Capital**

+44 (0)20 7408 4090

**(Nominated Adviser and Broker to OBD)**

Stephane Auton

Lucy Bowden

**WG Partners**

+44 (0)20 3705 9330

**(Joint Broker to OBD)**

David Wilson / Claes Spång /

Satheesh Nadarajah / Erland Sternby

**Vigo Consulting**

+44 (0)20 7390 0230

**(Media / Analyst enquiries for OBD)**

obd@vigoconsulting.com

Rozi Morris

**Notes for Editors**

**About Oxford BioDynamics Plc**

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the [EpiSwitch® PSE](#) (EpiSwitch Prostate Screening

test) and [EpiSwitch® CiRT](#) (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, [www.oxfordbiodynamics.com](http://www.oxfordbiodynamics.com), X (@OxBioDynamics) or [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

SPMTJBFTMTIMBMI